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ABSTRACT
Background
Pharmaceutical costs are the fastest-growing health-care expense in most developed
countries. Higher drug costs have been shown to negatively impact patient outcomes. Studies
suggest that doctors have a poor understanding of pharmaceutical costs, but the data are
variable and there is no consistent pattern in awareness. We designed this systematic review to
investigate doctors’ knowledge of the relative and absolute costs of medications and to
determine the factors that influence awareness.
Methods and Findings
Our search strategy included The Cochrane Library, EconoLit, EMBASE, and MEDLINE as well
as reference lists and contact with authors who had published two or more articles on the topic
or who had published within 10 y of the commencement of our review. Studies were included
if: either doctors, trainees (interns or residents), or medical students were surveyed; there were
more than ten survey respondents; cost of pharmaceuticals was estimated; results were
expressed quantitatively; there was a clear description of how authors defined ‘‘accurate
estimates’’; and there was a description of how the true cost was determined. Two authors
reviewed each article for eligibility and extracted data independently. Cost accuracy outcomes
were summarized, but data were not combined in meta-analysis because of extensive
heterogeneity. Qualitative data related to physicians and drug costs were also extracted. The
final analysis included 24 articles. Cost accuracy was low; 31% of estimates were within 20% or
25% of the true cost, and fewer than 50% were accurate by any definition of cost accuracy.
Methodological weaknesses were common, and studies of low methodological quality showed
better cost awareness. The most important factor influencing the pattern and accuracy of
estimation was the true cost of therapy. High-cost drugs were estimated more accurately than
inexpensive ones (74% versus 31%, Chi-square p , 0.001). Doctors consistently overestimated
the cost of inexpensive products and underestimated the cost of expensive ones (binomial test,
89/101, p , 0.001). When asked, doctors indicated that they want cost information and feel it
would improve their prescribing but that it is not accessible.
Conclusions
Doctors’ ignorance of costs, combined with their tendency to underestimate the price of
expensive drugs and overestimate the price of inexpensive ones, demonstrate a lack of
appreciation of the large difference in cost between inexpensive and expensive drugs. This
discrepancy in turn could have profound implications for overall drug expenditures. Much
more focus is required in the education of physicians about costs and the access to cost
information. Future research should focus on the accessibility and reliability of medical cost
information and whether the provision of this information is used by doctors and makes a
difference to physician prescribing. Additionally, future work should strive for higher
methodological standards to avoid the biases we found in the current literature, including
attention to the method of assessing accuracy that allows larger absolute estimation ranges for
expensive drugs.
The Editors’ Summary of this article follows the references.
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Financial constraints are a reality in almost all aspects of
medicine. Pharmaceutical expenditure ranges from 8.5% to
29.6% of health-care spending within Organisation for
Economic Co-operation and Development countries and is
increasing faster than other areas of health-care spending in
almost all these countries [1]. For example, in Canada
pharmaceutical spending increased from 9.5% of total health
care costs in 1985 to over 16% in 2004, and its annual growth
rate has exceeded that of all health expenditures in every year
in that period [2]. Most countries struggle to reduce
pharmaceutical spending [3,4] as escalating costs and limited
resources threaten other budgetary priorities. While the
policy makers in publicly funded systems and insurance
agencies struggle to cope, strategies to shift costs, in part or
whole, to the consumer are unavoidable. Unfortunately, these
initiatives often shift costs to other areas of health care, result
in worse patient outcomes, and are not cost-effective overall
[5–10]. Initiatives that have targeted doctors to reduce
pharmaceutical spending include guidelines, fund-holding,
and others [11–13]. One way of helping to control drug costs
would be for physicians to autonomously choose the least-
costly medication when there are no substantial differences
in safety and effectiveness between the least and most
expensive. Price variations within drug classes [14,15] or
between drug classes are common, and if physicians were to
choose therapeutically equivalent but less-expensive drugs,
large scale savings could be realized.
In addition to budget concerns, doctors must consider drug
costs to their patients. Increasing pharmaceutical costs
negatively impacts patients in two ways. First, high direct
expenses for those of limited resources may mean a choice
between medicines and necessities such as food or clothing
[16,17]. Alternatively, patients who do not take their medicine
as directed or go without the potentially beneﬁcial therapies
entirely [16,17] often suffer negative health consequences [5–
8,10]. Unfortunately, patients may be too embarrassed to tell
their physicians when they cannot afford their medicines
[18,19].
Background: Drug Costs and Patient Expenses
In the global market, the cost of drugs is highly variable and
therefore obtaining accurate and relevant costs is often very
complex. The situation in the United States (US) is likely the
most complex, and multiple authors have attempted to distil
the confusing and convoluted story of drug costs [20,21]. The
often-quoted average wholesale price (the distributors’ price
to pharmacies) can vary due to multiple factors such as
demand, recent negotiations with pharmaceutical manufac-
turers, and changes in coverage from large insurers. At the
pharmacy, mark-up of the average wholesale price can be
dramatic depending on the type of product (acute medicines
have a larger mark-up) or the method of payment (cash
customers often pay more). Alternatively, some high-use
drugs may be marked down to draw customers in to the store.
The amount the patient pays is based on his or her insurance,
through private organizations such as managed care organ-
izations and health maintenance organizations, government
support (for example, Medicaid), or a combination of the
above (families may have two or more providers). Insurers use
a wide variety of strategies to control costs including
copayment, tiered copay (the amount of shared payment
varies with different drugs), and reference pricing for drugs,
to name a few. Each insurer (private or government) covers
different drugs and have different copay systems (ﬂat fees,
percent copay, or a mixture of the two).
Elsewhere, the system is slightly less complex. In Canada,
drug prices are believed to more closely parallel the wholesale
price but are still subject to some of the variations and price
competition found in the US. There is provincially based
drug coverage for seniors and low-income individuals, but
many provinces have some form of copay or reference -based
pricing. The rest of the population pays for drugs out of
pocket or has some form of insurance (which frequently has a
copay component). In Europe, there are dramatic (.400%)
differences in drug costs between neighboring countries
[22,23]. Many countries have some elements of price
competition (e.g., United Kingdom [UK] and Germany), but
in some countries companies negotiated costs with regional
(e.g., Spain) or federal (e.g., Italy) governments [24]. Many
countries, including UK, France, Germany, Italy, The Nether-
lands, Spain, Finland, Denmark, and Austria, have some form
of copay [3,23]. The copay systems are often added to a mix of
complementary insurance (e.g., France), reference-based
pricing (e.g., The Netherlands), drug budgets for physicians
(e.g., UK), price control (e.g., Italy) and combinations of them
all with regional variation in some countries [3]. The systems
are at times irrational. For example, ﬁxed copayments in
some countries can result in patients paying more for a
prescription than the actual list price of the drug [23].
Although many North Americans believe that drugs are free
to patients in Europe, copayments have been shown to be a
barrier for patients even in the UK [19]. Many other countries
(e.g., Australia and Japan) also use a variety of copayment or
cost-sharing schemes for prescriptions [24,25].
Therefore, with global budgets a concern and the welfare of
patients at risk, physicians need to consider drug cost when
prescribing. If physicians are going to take costs into
consideration they need to be cognizant of both the absolute
drug cost and the relative differences between prices of
products. However, in most places cost information is not
easily available for doctors and even where it is, the large
difference between inexpensive and expensive equivalents is
not emphasized. To determine if it is necessary to enhance
both physicians’ education about prices and the availability of
that information, we undertook a systematic review to
determine physicians’ level of awareness of the cost of
prescription drug products.
Methods
Templates for systematic review of survey studies are not
well established, but QUOROM [26] (normally reserved for
systematic reviews of randomized controlled trials) is a good
guide for most systematic reviews and was used here wherever
possible (Table S1).
Search
We searched the Cochrane Library (from 1966), EconLit
(from 1969), EMBASE (from 1974), and MEDLINE (from 1950)
up to 31 May 2005 using the search terms ‘‘physician’’,
‘‘doctor’’, ‘‘medical student’’, ‘‘house staff’’, ‘‘intern’’ or
‘‘resident’’; ‘‘medicine’’, ‘‘medications’’, ‘‘drug’’, ‘‘therapeu-
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‘‘price’’; and ‘‘knowledge’’, ‘‘awareness’’ or ‘‘understanding’’.
The original search attempted to capture all cost awareness
studies including those in which doctors estimated the costs
of investigations (knowledge of the cost of investigations will
be presented in another publication). The titles and abstracts,
where available, were independently screened by GMA and JL
and if either investigator thought that the article would be
potentially eligible, a complete copy was obtained. To
identify additional studies, the reference list of any poten-
tially eligible article was searched and authors with two or
more publications in the area or who had published in the 10
y preceding the start of our review were contacted.
Eligibility
Articles were included if: either doctors, trainees (interns
or residents), or medical students were surveyed; there were
more than ten survey respondents; costs of pharmaceuticals
were estimated; results were expressed quantitatively; there
was a clear description of how authors deﬁned ‘‘accurate
estimates’’; and there was a clear description of how the true
cost was determined. Because costs are variable and complex,
we felt it was only reasonable for doctors to have knowledge
of the total costs of the prescription, whether that cost was
borne partially or completely by the patient and/or the
insurer (private or government), in their local practice
environment. Therefore, ‘‘true cost’’ was operationally
deﬁned as the actual cost the study authors veriﬁed from
one or more locally relevant reliable sources for each drug in
their study. This source would vary by location, but in the UK
d r u gp r i c e sa r em o r eu n i f o r ms ot h eB r i t i s hN a t i o n a l
Formulary would be a reasonable source, while in US quotes
from local pharmacies (averaged from a broad sample) is
most appropriate [21]. The deﬁnition of ‘‘accurate estimates’’
was taken from the authors and typically fell within a deﬁned
‘‘accuracy range’’ (e.g., 625%) around the true cost. Articles
were excluded if they were not published in English or if
participants were asked to estimate costs within ranges or
cost increments only (for example ‘‘please estimate which $20
cost category/range is most appropriate for drug A’’). GMA
and JL independently assessed each potential article for
eligibility. Differences in decisions about inclusion and
exclusion were resolved through consensus.
Data Extraction
From each eligible article GMA and JL independently
extracted the following information: publication year; study
country; response rate and number of participants, sample
selection method (random, entire speciﬁed population,
convenience); mode of survey administration (postal, hospital
mail, meeting, face-to-face); participant level of training
(medical student, intern, resident, qualiﬁed doctor); specialty;
number of different drugs estimated; method of ascertain-
ment of true cost (from formulary, acquisition cost, amount
billed to patient, survey of retail pharmacies, wholesale price);
method of assessing accuracy of cost estimate (within a
speciﬁed percent or dollar range of true cost); and estimation
accuracy (percent of respondents with accurate estimate,
percent above and below true cost, median percent error of
estimations). Primary quality measures were method of
sample selection, mode of survey administration, and
response rate, as well as errors or unclear description of
calculations (e.g., incorrect method of calculating estimation
error). This selection was based on our understanding of the
places where the greatest biases can occur in survey studies.
Where data were not reported in a way that allowed
extraction in one of our categories, we attempted to calculate
the information from available data (e.g., number of
respondents calculated from the number of surveys distrib-
uted multiplied by the response rate). Comparisons within
studies, such as differences between medical student and
resident accuracy, were extracted when available. Qualitative
information, such as surveys of physicians’ opinions, was also
extracted when available. Authors were contacted for further
data where necessary. After each investigator independently
extracted the above information, the results were compared
and differences resolved by consensus.
Data Analysis
The studies were too diverse to pool meta-analytically (e.g.,
different therapies, different cost estimation procedures,
different groups of physicians), but we did examine accu-
racies by grouping studies with nonparametric summaries.
Mean accuracy (expressed as the percent of physicians who
correctly estimated drug costs) for each study was calculated
by averaging the accuracy from each participant group or
drug estimated with weighting for the number of estimation
attempts. For example, if accuracy was 30% for drug A (n ¼
100) and 50% for drug B (n¼80), the average accuracy would
be 39% ([(0.30 3 100) þ (0.5 3 80)] 4 180). We calculated
nonparametric summaries (median and ranges [minimum –
maximum]) for the following outcomes: average cost accuracy
(within deﬁned percent margins of error), average percent of
estimates over and under true cost, average percent of
estimates over and under the margins of error (as deﬁned by
the original authors) around the true costs, and average
percent error (jestimate – true costj/true cost).
Percent error is the statistic used to demonstrate the
degree of estimation error. To be reliable, each estimate
error (the amount above or below the true cost) must be
converted to an absolute value. If it is not, high estimates will
be positive numbers and low estimates will be negative
numbers, and when summed will partially cancel each other
giving a lower value and a false impression of accuracy. For
example, if the true cost of a drug is $100 a month and two
doctors estimate $50 and $150 respectively, the correct
percent error would be 50%. However, if absolute values
were not used, the percent error of the high estimation error
would be 50% and the low would be 50%. This would make
the combined percent error 0%, indicating no error in
estimation and yielding a false representation of perfect
accuracy.
Additionally, a priori-deﬁned subgroups, such as year of
publication (divided by median year of publication of
studies), location of study, training level of participants, and
specialty were examined to determine if these variables
inﬂuenced the accuracy of the cost estimation. We also
examined the inﬂuence of study quality on estimation
accuracy by separating studies with a similar accuracy range
into those of high, mid, and low quality. For this analysis, we
used weaknesses of response rate ( 50% or unclear),
sampling method (convenience or unclear), and survey
distribution (unclear) as markers of quality. While there is
no deﬁned adequate response rate, low response rates can
PLoS Medicine | www.plosmedicine.org September 2007 | Volume 4 | Issue 9 | e283 1488
Physician Awareness of Drug Costbias surveys [27,28] and we felt 50% was generous. Non-
probability sampling, such as convenience sampling, can bias
studies because the sample is not representative of the
population. Different modes of questionnaire administration
have different inherent biases, and while there is no clearly
superior method [29], we felt the information was important
in reviewing surveys. High-quality studies had none of these
weaknesses, mid-quality studies had a single weakness, and
low-quality had two or more weaknesses. In post hoc analyses,
where studies reported potential within-study factors inﬂu-
encing the accuracy of cost estimation (e.g., cost of drug), we
used the binomial test to combine ‘‘votes’’ across studies.
We also performed two sensitivity analyses. To minimize
the heterogeneity inherent to comparing studies with multi-
ple different drugs, we compared the average cost accuracies
for speciﬁc drugs common among three or more studies.
When data cannot be combined and nonparametric statistics
such as medians and ranges must be used, there is a concern
that larger studies are weighted equally with smaller ones. To
determine the potential inﬂuence of ‘‘weighting,’’ we per-
formed sensitivity analyses where the median nonparametric
statistic was selected based on the number of therapies in
each study, the number of physicians in each study, or the
total number of estimates in each study.
Ethics approval was not required as the research involved
publicly available material.
Results
Literature Search and Study Selection
A study ﬂow diagram is provided in Figure 1. Eleven
authors were contact to identify possible studies and six
responded, to yield two previously unidentiﬁed studies. From
a total of 2,954 studies, 24 were included in the systematic
review (Table S2 provides the list of articles excluded after
full review and the reason for exclusion). Disagreement
between reviewers was rare (2% in eligibility and 6% in data
extraction).
Study Characteristics
The main characteristics and methodological aspects of
each study are provided in Table 1. Studies were conducted
from 1978 to 2004 in six countries, with the US (nine studies),
UK (eight), and Canada (four) predominating. Eleven studies
included licensed physicians only, two involved house staff
only, and 11 included a mixture of participants. Eight studies
involved general practitioners (GPs) alone, seven speciﬁc
specialists groups, six a mix, and three were unclear as to the
specialty of the doctors.
Hospital-based studies in Canada, Denmark, Italy, India,
and the UK deﬁned true costs with formulary lists from the
hospital [30], government formularies [31,32], wholesale costs
paid by the hospital [33,34], or total cost to the hospital [35–
37]. The only US study of in-hospital physicians used hospital
charges as true costs [38]. Most US outpatient studies [39–45]
used the averaged prices from surveys of local pharmacies to
determine true costs, but one [46] used the average wholesale
price. Most of the remaining outpatient studies from Canada
and the UK, where price varies little from the single-payer
agreed reimbursement, determined true cost from single
sources such as the wholesale costs [47,48] or the British
National Formulary [49–52]. One Canadian study used a
pharmacy survey for outpatient prescribing and cost to the
hospital for inpatient prescribing [53].
The majority of studies (79%) selected drugs based on the
common drugs for that specialty. The others picked agents
based on speciﬁc representative mixes of generic/branded
medications [41,50–52] or based on cost impact by frequency
and expense [35]. Only two studies speciﬁcally identiﬁed the
percent of generics (30% [46] and 39% [52]), but it appears
the proportion in studies overall was approximately 50%.
Study Quality
Quality and methodological reporting were poor in most of
the studies. The method of survey distribution was unclear in
seven studies, and sampling was convenience or unclear in 12
studies. The response rates were   50% or unknown in seven
studies. Only seven (29%) of 24 studies [30,39,45,47,50–52] did
not have any of these three weaknesses. In addition, of 12
studies attempting to quantify the degree of estimation error
(for example percent error), nine used average estimations
without regard for signage (that is, averaging overestimates
with underestimates) or inadequately described the calcu-
lation. In total, 19 (79%) of the 24 studies had one or more of
these four weaknesses, and only ﬁve trials [30,39,47,50,51]
were without substantial weaknesses. There was also a large
variation in study design; ﬁve methods were used to
determine true costs, and reasonable accuracy was deﬁned
nine different ways.
Estimation Accuracy
Table 2 summarizes cost estimation accuracy outcomes. In
general, average estimation accuracy was less than 50%,
decreasing with tighter deﬁnitions of accuracy. Overestima-
tion tended to be more frequent than underestimation, and
Figure 1. Study Identification and Selection Process
doi:10.1371/journal.pmed.0040283.g001
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sensitivity analyses of the most commonly used margin of
error (620% or 625%), the number of therapies, the number
of physicians, or the number of estimates from each study did
not change the median cost accuracy by more 2%. This
ﬁnding demonstrates that weighting would not have inﬂu-
enced the ﬁnal result and that the median accuracy is very
similar to a weighted mean if the data could have been
combined.
Table 3 presents nonparametric summaries for subgroups
using the most commonly used margin of error (620% or
625%). Results were similar using the 650% or 50%–200%
margin of error (unpublished data). While dramatic differ-
ences were not apparent, the quality of the studies may play a
role in reporting the accuracy of cost estimation. By
comparison, the highest-quality studies had a median
accuracy of 29% (range 16%–33%) while the lowest quality
studies had a median accuracy of 38% (range 27%–45%).
There is large estimation variability within studies (percent
error), and between studies accuracy varied widely (for
Table 1. Study Characteristics
Author Publication
Year
Country Participants’
Training
Level
Specialty Number of
Therapies
Number
Responding
(Response
Rate as %)
Sample
Selection
Mode of
Survey
Administration
True Cost
Determined
from
Allan 1 [47] 2002 Canada HS GP 20 82 (85) Entire Meeting/mail Wholesale
Allan 2 [48] 2004 Canada Lic GP 20 283 (47.2) Random Mail Wholesale
Bailey [31] 1993 UK Lic, HS Anesthesia 15 40 (100) Convenience Face to face Formulary
Beringer [39] 1984 US Lic, HS Neurology 39 24 (75) Entire Mail Survey
Conti [30] 1998 Italy Lic, HS Mix 15 60 (100) Random Face to face Acquisition
Dresnick [38] 1979 US Lic, HS, MS Mix 3 427 (ns) Unclear Unclear Billing
Fairbass [33] 1988 UK Lic Anaesthesia 17 20 (100) Unclear Unclear Acquisition/wholesale
Fink [40] 1978 US Lic Mix 22 114 (31.2) Random Mail Survey
Glickman [41] 1994 US Lic Mix/GP 14 132 (80
a) Convenience Meeting Survey
Innes [35] 2000 Canada Lic Emergency 20 75 (100) Convenience Face to face Survey
Mills [34] 1993 UK Lic Anaesthesia 17 20 (100) Convenience Face to face Wholesale
Mishra [32] 1998 India Lic, HS ns 6 42 (ns) Unclear Unclear Wholesale
Oppenheim [42] 1981 US Lic, HS GP 10 152 (68.2) Mix Unclear Survey
Perrine [43] 1982 US Lic, HS GP 15 58 (48
b) Unclear Unclear Survey
Ringenberg [44] 1988 US HS GP 18 65 (72) Convenience Meeting Survey
Rowe [49] 1986 UK Lic, HS Mix/GP 15 50 (100) Unclear Unclear Formulary
Ryan 1 [50] 1990 UK Lic GP 21 281 (76.6) Mix Mail Acquisition
Ryan 2 [51] 1992 UK Lic GP 21 244 (61) Random Mail Acquisition
Safavi [45] 1992 US Lic, HS Mix/GP 5 188 (71) Entire Hospital mail Survey
Schlunzen [36] 1999 Denmark Lic Anaesthesia 19 47 (92.2) Unclear Hospital mail Survey
Silcock [52] 1997 UK Lic GP 31 627 (62.7) Random Mail Formulary
Walzak [46] 1994 US Lic, HS Mix/GP 20 137 (50) Random Mail Wholesale
Weber [53] 1986 Canada Lic, HS, MS Pediatrics 6 71 (90) Unclear Mail/face to face Acquisition/survey
Wynick [37] 1985 UK Lic ns 2 82 (48) Entire Unclear Acquisition
HS, house staff; Lic, licensed physicians; Mix, mixture of specialized physicians; MS, medical students; ns, not specified.
aExact response rate and number surveyed not given (‘‘.80%’’ stated)
bExact number surveyed unclear (‘‘approximately 120’’) so response rate approximate.
doi:10.1371/journal.pmed.0040283.t001
Table 2. Cost Accuracy Summaries
Definition Number of Studies Median (Range), % References
Within 610% or 615% 4 15 (9–26) [32,38,39,43]
Within 620% or 625% 12 31 (16–51) [30,32,35,38,40,43,47,48,50–53]
Within 650% or 50%–200% 9 44 (32–60) [31,33,34,36,37,44,47–49]
Overestimation
a 4 68 (60–86) [33,34,47,48]
Underestimation
a 4 32 (14–40) [33,34,47,48]
Above 120/125%
b 6 39 (16–49) [32,40,50–53]
Below 75/80%
c 6 23 (18–48) [32,40,50–53]
Percent error
d 3 243 (218–301) [35,47,48]
aPercent of estimates over or under the true cost.
bPercent of estimates above the 20% or 25% acceptable margin of error around the true cost.
cPercent of estimates below the 20% or 25% acceptable margin of error around the true cost.
dCalculated as jestimate – true costj/true cost.
doi:10.1371/journal.pmed.0040283.t002
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from 16% to 51%). When some heterogeneity is reduced by
focusing on estimation accuracy for the same drugs, the
variability between studies persists (Figure 2).
Factors Influencing Estimation Pattern and Accuracy
Table 4 summarizes the results of subgroup comparisons
within included studies. Very few variables impacted the
estimation of cost. Two studies [39,42] of three found cost
estimations of nonacademic physicians more accurate than
academic physicians. The most consistent factor inﬂuencing
the pattern of estimation was the true cost of the therapy. All
11 studies that examined the inﬂuence of drug price on
estimation patterns found that expensive drugs are consis-
tently underestimated and inexpensive drugs are consistently
overestimated. This ﬁnding was reinforced in the ﬁve studies
[35,47,48,50,51] that provided enough data (true cost and the
percentage of high/low estimations for each drug) to examine
the effect of drug cost on the estimation pattern for
individual drugs. For 89 of the 101 drugs in these studies,
doctors consistently overestimate the cost of inexpensive
drugs and underestimate the cost of expensive drugs
(binomial test, 89/101, p , 0.0001).
Six studies [35,43,47,48,50,51] provided enough data (true
cost and estimation accuracy for each drug) to examine the
implication of the true drug cost on the estimation accuracy
for individual drugs. Expensive drugs are generally estimated
more accurately: compared to the mean estimation accura-
cies for the studies, only 23 (31%) of 74 inexpensive drugs had
a higher estimation accuracy while 32 (74%) of 43 of
expensive drugs had a higher estimation accuracy (Chi-
square, p , 0.001).
The inﬂuence of physician membership in a health
maintenance organization or managed care organization is
uncertain because US outpatient studies involved large
communities and did not speciﬁcally examine or identify
physicians within these organizations. One UK community
study [52] compared estimation accuracy of fund holders to
non-fund holders and users with desktop computer cost
information to those without and found no difference except
for a slightly (2%, p ¼ 0.01) improved awareness among fund
holders for inexpensive and very inexpensive drugs. However,
the authors acknowledge that weaknesses in the computer
program may have limited the utility of cost information, and
the higher awareness may be due to selection bias because
physicians chose to be fund holders and likely had a prior
interest in costs [52].
Qualitative Information
Many of the studies collected additional qualitative cost
information. When asked, doctors rated their cost awareness
as low in ﬁve of ﬁve studies [39,40,45,46,48], rated their
previous cost education as low or absent in ﬁve of ﬁve studies
[30,39,42,44,48], and stated that costs are important in eight
of eight studies [41,42,45–48,50,52]. In four of four studies
doctors reported that cost information is not easily accessible
[41,46,48,50] but that they wanted more cost information
[45,46] and that it would change their prescribing [48,50,52]
without negatively impacting patient care [50,52], or would
improve patient care [46].
Discussion
Physicians’ awareness of the cost of therapeutics is poor.
With only 31% of estimates within 20% or 25% of the true
drug cost and the median estimate 243% away from the true
cost, many of the estimates appear to be wild guesses.
Country, level of training, specialty, and other factors seem
to have little impact on the degree of awareness. Despite
substantial and increasing concern about costs, doctors’
awareness has not improved in the 26-year span of these
studies. Estimation accuracy does not appear to differ among
the three countries—Canada, UK, or US—where the vast
majority of the studies were conducted nor in the other
countries (India, Denmark, Italy) represented in the included
studies. Direct comparison of awareness between countries is
limited because no study simultaneously surveyed doctors
from different countries. Comparison of the estimation
accuracy for the same drug across different studies showed
persistent inaccuracies in the estimation patterns. This
pattern suggests that removing some of the heterogeneity
does not improve estimation variability, and poor awareness
of cost is pervasive among physicians.
Common wisdom would have it that doctors’ knowledge of
drug costs is poor, and at this level our study seems to add
little to what is already known. However, what is unique to
Table 3. Between-Study Comparisons in Cost Accuracy (for Studies Using 20% or 25% Margins of Error for Accuracy)
Variable Category Number of Studies Median (Range), % References
Country UK 3 29 (26–33) [50–52]
Canada 4 23 (16–51) [35,47,48,53]
US 3 33 (27–38) [38,40,43]
Training Licensed 6 31 (23–33) [35,40,48,50–52]
Mixed 5 38 (16–51) [30,32,38,43,53]
Year study published  1990 5 33 (27–51) [33,40,43,50,53]
 1991 7 23 (16–45) [30,32,35,47,48,51,52]
Physician Generalist 6 28 (16–33) [43,47,48,50–52]
Specialist 5 33 (16–51) [30,35,38,40,53]
Quality
a High 5 29 (16–33) [30,47,50–52]
Mid 4 28 (23–51) [35,40,48,53]
Low 3 38 (27–45) [32,38,43]
aSee text for definition of quality.
doi:10.1371/journal.pmed.0040283.t003
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Physician Awareness of Drug Costour systematic review is the ﬁnding that no factors inﬂuence
physicians’ drug price awareness or estimation pattern except
for the cost of the drug. The demonstration that estimation
accuracy improves with higher-cost drugs is almost certainly
not due to improved awareness of the cost of expensive drugs,
but simply reﬂects the method used to measure awareness
that grants larger absolute margins of error for more-
expensive drugs. For example, when accuracy is deﬁned as
within 25% of the true cost, doctors’ estimations have to be
within $0.25 of a drug that cost $1.00 a month to be accurate,
whereas they could be $25 off from a $100-per-month drug
and still be accurate. While this ﬁnding should not be
interpreted as physicians having better cost awareness of
expensive drugs, an understanding of the bias in this method
of assessing accuracy is helpful in explaining the variability in
accuracy within and between studies. For example, from
Figure 2 we can see that estimation accuracy is highly variable
for cimetidine and that it is estimated more accurately in
Ryan 1 [50], Ryan 2 [51], and Perrine [43] than in Allan 1 [47]
and Allan 2 [48]. Cimetidine was the second most expensive
drug in Ryan 1 [50] and Ryan 2 [51] and the most expensive in
Perrine [43], allowing larger margins of absolute error. In
Allan 1 [47] and Allan 2 [48] cimetidine was a low-cost drug
and therefore had narrower margins of error. Correspond-
ingly, studies can appear to have higher accuracies due to
higher proportions of expensive drugs.
Perhaps the most valuable ﬁnding of our review is how a
drug’s cost inﬂuences the pattern of a doctors’ estimation and
how that reﬂects doctors’ understanding of drug costs. In the
movement to contain health-care costs it is extremely
important to recognize the consistent lack of appreciation
of the large difference in cost between inexpensive and
expensive drugs. The erroneous perception of minimal
differences in true costs could have profound implications
for overall drug expenditures. Even if a doctor was concerned
about costs and was aware that one drug was more expensive
than another, he or she might still choose that expensive drug
because of a belief that the cost difference is small. For
example, if the doctor of a patient with uncomplicated
hypertension does not realize the large price difference
between the high- and low-cost products (e.g., in the province
of Ontario the daily cost for hydrochlorothiazide, a thiazide
diuretic, is CAN$0.01 versus CAN$1.05 for valsartan, an
angiotensin 2 receptor antagonist), she or he may prescribe
the more-expensive agent. In this case, there is a 100-fold
difference in prices, and over ten years this difference would
amount to additional expenditure of almost CAN$3,800 for
one drug, and perhaps more, because multiple medications
are often required for the control of hypertension. This is an
exceptional expense for many patients, but if we consider the
large number of patients on antihypertensives, the cost to
third parties is ampliﬁed remarkably. New drugs are generally
more expensive than existing ones and therefore the lack of
knowledge about the magnitude of the difference between
less- and more-expensive drugs will continue to fuel the
growth in drug expenditures as more new products come on
the market.
Unfortunately, methodological weaknesses were common
among the studies. Low response rates, convenience or
unclear sampling, and unclear survey distribution are
frequent weaknesses in cost awareness research, and these
factors appeared to play a role in the study outcomes. While
Figure 2. Comparison of Accuracy for Similar Drugs
Comparison of estimation accuracy (within 20% or 25% margin of error) of the same drug among different studies.
doi:10.1371/journal.pmed.0040283.g002
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Physician Awareness of Drug Costmost studies had at least one methodological weakness, six
(25%) of them had two or more weaknesses, and these studies
seem to have a bias in favour of inﬂating doctors’ cost
awareness. Where only the higher-quality studies were used,
physician awareness of costs became even poorer. Future
research should focus on a large, deﬁned sample of physicians
(not a convenience sample), clarify the method of survey
distribution, use methods to enhance response rates [27,54],
and simultaneously survey doctors from different countries
about a common group of drugs. There should be a clear
description of true cost, use of comparable accuracy margins,
and appropriate calculation of percent error (absolute
numbers). Future authors should be aware of the bias
associated with percent margins of error and the correspond-
ing broader absolute margins with expensive drugs. They may
want to consider doing additional analyses linking accuracy
with decreasing margins of error for increasing true cost. It is
important to correct these methodological deﬁciencies in
order to be able to accurately determine if techniques to
increase awareness of costs have had any inﬂuence on
doctors’ knowledge and behaviour.
While many people believe that doctors do not care about
costs, secondary ﬁndings in the cost awareness studies show
that doctors feel costs are important, and these ﬁndings are
echoed in surveys of physicians’ opinions of cost [55–57].
Swiss doctors feel costs, even to third-party payers, are
important [55]. In the US, while 91% of doctors reported that
costs are important when patients pay out-of-pocket, 80%
felt that total (third-party) costs were also important [57]. A
qualitative UK study found doctors give considerable thought
to cost in their prescribing decisions in the context of
ensuring quality of care [56]. Comments in some of the cost
awareness studies indicate that doctors recognize the limits of
their knowledge about costs, want more information, and feel
that the provision of such information would reduce costs
and either improve care or at least not negatively impact
care. Despite this desire for more information and the
potentially positive impact of providing it, doctors feel cost
information is not accessible and some researchers even
report signiﬁcant challenges in obtaining cost information
[35,44].
Application of this Systematic Review
Studies in Israel [58,59] have demonstrated that in
simulated cases, the addition of cost information modiﬁes
prescribing decisions in favour of reduced costs. A similar
Canadian study [60] found that doctors did choose higher-
cost drugs for patients with third-party coverage, but were
sensitive to costs when provided and reduced expensive
prescribing for covered drugs as well. These studies show the
assumption that doctors are unconcerned about costs is
mistaken. Rather, doctors feel that all costs (out-of-pocket
and total) are important, they consider cost when prescribing
and are sensitive to cost information. Therefore, more needs
to be done to help physicians make costs part of their
prescribing decisions.
Two studies [61,62] found that providing cost information
alone as part of a program of computer prescribing did not
reduce costs; however, in both cases the cost information was
provided only once the drug choice was made, cost
alternatives had to be sought, and in one [61], a relative
score rather than the actual price was given. Furthermore, the
before–after design led to bias because other coincidental
initiatives caused inﬂation of drug costs during the inter-
vention period [62].
Although data are limited, respondents in the cost
awareness surveys indicated doctors’ past cost education
was limited, and in a recent US survey 89% of medical
students indicated they wanted more education in health-
care policy [63]. Clearly, more emphasis is required in the
education of physicians about cost, and that education should
likely start with improving the awareness of university faculty
and medical school teachers. This is not to say doctors need
to be educated about the cost of individual pharmaceuticals:
As mentioned previously, that information varies dramati-
cally and changes frequently, and physicians are already
coping with information overload [64]. General cost educa-
tion in medical school and residency should include an
explanation of the large price differences between inexpen-
sive and expensive drugs, the economies of time and scale,
local coverage or copayment strategies, and perhaps that
rising drug cost negatively impact funding to other areas.
In the clinical setting, providing cost information to
doctors has had varying but generally positive results. Most
Table 4. Impact of Different Factors on Accuracy of Cost Estimation
Factor No Consistent Difference
(Number of Studies)
Consistent Difference
(Number of Studies)
References
Urban versus rural physician 3 [47,48,50]
Academic versus nonacademic physician 1 2
a [39,42,48]
Physician level of training 14 [30,31,32,36–38,42–46,48,49,53]
Cost of the drugs (high versus low cost) 11
b [30,31,34–36,41,47,48,49–51]
Physicians’ years in practice 5 [30,41,46,48,50]
Physician gender 3 [47,48,50]
Physician specialist/GP 4 1
c [38,40,41,45,49]
Physician reported training in cost 2 [44,48]
Physicians’ self-assessed awareness 3 [42,48,49]
Physicians reporting costs important 2 [47,48]
aNonacademics provided more accurate drug cost estimates than academics.
bHigh-cost pharmaceuticals are underestimated and low-cost ones are overestimated.
cAccuracy of internal medicine specialists slightly lower than GPs.
doi:10.1371/journal.pmed.0040283.t004
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Physician Awareness of Drug Coststudies show that providing cost information, particularly if
combined with education and/or feedback, can modify
prescribing and reduce costs [65–71]. Without directly
providing cost information, other studies have shown that
audit and feedback [72,73], educational interventions [74],
and computerized prescribing with reminders [73,75] or
evidence-based decision support [76] can all reduce costs.
Cost information could easily be incorporated into
computerized prescribing software, giving doctors immediate
information at the point of care. Physicians are rushed for
time and typically spend less than two minutes to answer
their clinical questions [77,78] so searching published docu-
ments or accessing other websites for cost information is not
a realistic task. Even though some locations have cost
information in prescribing software, it is not complete. For
instance, in Australia where 98% of GPs use computer
prescribing software [79], the pricing ﬁelds in the software
are not uniformly ﬁlled in and limitations in the software may
affect its utility [62].
While helpful, the measures proposed above are unlikely to
have much impact in isolation, and most successful efforts in
changing physician behaviour are multifactorial [80]. For
instance, prescribing software does not present doctors with
the relative costs of alternative treatments. If doctors are not
aware that large differences can exist in the price of
medications used for the same indication, they may continue
to prescribe the more expensive varieties, especially if these
drugs are being heavily promoted.
Therefore, real-time computerized prescribing software
with cost information should also be linked with evidence-
based decision support, which has been shown to reduce cost
[76] as well as medication errors [81]. This information should
be supplemented with real-time data on the relative costs of
therapeutically equivalent medications. Additionally, physi-
cians should also receive feedback and cost information and
education, preferably personalized and rapid, similar to what
has been delivered in the studies that have demonstrated
reductions in prescribing costs [66,67,69,70]. Unfortunately,
the most established audit–feedback system (PACT, or
prescribing analysis and cost, in the UK) is mailed and arrives
three to four months after the prescribing decisions have
been made.
Future research should focus on programs that provide a
combination of initial basic cost education, absolute and
relative cost information integrated into point-of-care
prescribing (preferably with evidence-based decision sup-
port), and ongoing audit–feedback and education. Due to
expenses, audit–feedback and education would likely be most
efﬁcient if targeted on high-use drugs that have low-cost
alternatives. The research should be randomized, prospective
trials (not before/after) with control groups, and savings
should be compared to program expenses.
Limitations
A potential weakness of our study is the exclusion of non-
English studies. From the abstracts of the non-English studies
we identiﬁed, the estimation accuracy was 18% and 41%,
indicating that inclusion would likely not have altered our
ﬁndings signiﬁcantly [82,83]. Only three of the studies
included in our review were done after 1999, and con-
sequently our results may not reﬂect current cost awareness
of doctors. Of 24 studies, 21 came from the US, UK, and
Canada. Knowledge of costs could be different in other
countries, but studies from India, Italy, and Denmark had
similar results and we that feel cost awareness would likely be
similar in other countries.
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Editors’ Summary
Background. Many medicines are extremely expensive, and the cost of
buying them is a major (and increasing) proportion of the total cost of
health care. Governments and health-care organizations try to find ways
of keeping down costs without reducing the effectiveness of the health
care they provide, but their efforts to control what is spent on medicines
have not been very successful. There are often two or more equally
effective drugs available for treating the same condition, and it would
obviously help keep costs down if, when a doctor prescribes a medicine,
he or she chose the cheapest of the effective drugs available. This choice
could result in savings for whoever is paying for the drugs, be it the
government, the patient, or a medical insurance organization.
Why Was This Study Done? Doctors who prescribe drugs cannot be
expected to know the exact cost of each drug on the market, but it
would he helpful if they had some impression of the cost of a treatment
and how the various alternatives compare in price. However, systems
deciding how drugs are priced are often very complex. (This is
particularly the case in the US.) The researchers wanted to find out
how aware doctors are regarding drug costs and the difference between
the alternatives. They also wanted to know what factors affected their
awareness.
What Did the Researchers Do and Find? They decided to do a
systematic review of all the research already conducted that addressed
this issue so that the evidence from all of them could be considered
together. In order to do such a review they had to specify precise
requirements for the type of study that they would include and then
comprehensively search the medical literature for such studies. They
found 24 studies that met their requirements. From these studies, they
concluded that doctors were usually not accurate when asked to
estimate the cost of drugs; doctors came up with estimates that were
within 25% of the true cost less than one-third of the time. In particular
doctors tended to underestimate the cost of expensive drugs and
overestimate the cost of the cheaper alternatives. A further analysis of
the studies showed that many doctors said they would appreciate more
accurate information on costs to help them choose which drugs to
prescribe but that such information was not readily available.
What Do These Findings Mean? The researchers concluded that their
systematic review demonstrates a lack of appreciation by prescribing
doctors of the large difference in cost between inexpensive and
expensive drugs, and that this finding has serious implications for
overall spending on drugs. They call for more education and information
to be provided to doctors on the cost of medicines together with better
processes to help doctors in making such decisions.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040283.
  A brief guide to systematic reviews has been published by the BMJ
(British Medical Journal)
  The Web site of the Cochrane Collaboration is a more detailed source
of information on systematic reviews; in particular there is a
newcomers’ guide and information for health-care consumers
  The Kaiser Family Foundation, a nonprofit, private operating founda-
tion focusing on the major health care issues in the US, has a section
on prescription drugs and their costs
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